Cargando…

IL-22 production of effector CD4(+) T-cells is altered in SLE patients

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by T-cell-dependent B-cell activation and altered T-cell response. Co-stimulatory and co-inhibitory molecules regulate and exert T-cell differentiation, survival and cytokine production. CD134(+) and PD-1(+) T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolff, Sebastian, Scharpenberg, Claudia, Specker, Christof, Kribben, Andreas, Witzke, Oliver, Wilde, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643306/
https://www.ncbi.nlm.nih.gov/pubmed/31331400
http://dx.doi.org/10.1186/s40001-019-0385-6
_version_ 1783437100761219072
author Dolff, Sebastian
Scharpenberg, Claudia
Specker, Christof
Kribben, Andreas
Witzke, Oliver
Wilde, Benjamin
author_facet Dolff, Sebastian
Scharpenberg, Claudia
Specker, Christof
Kribben, Andreas
Witzke, Oliver
Wilde, Benjamin
author_sort Dolff, Sebastian
collection PubMed
description BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by T-cell-dependent B-cell activation and altered T-cell response. Co-stimulatory and co-inhibitory molecules regulate and exert T-cell differentiation, survival and cytokine production. CD134(+) and PD-1(+) T-cells in SLE patients are increased in SLE. The aim of this study was to characterize CD134(+) and PD-1(+)CD4(+) T-cells according to their ability to produce IFN-γ, IL-21 and IL-22 in SLE patients. METHODS: Peripheral blood of 39 SLE patients and 19 healthy controls (HC) was stimulated with phorbol myristate acetate (PMA) calcium ionophore (Ca-Io). The expression of IFN-γ, IL-21 and IL-22 T-cells within the CD134(+) and PD-1(+) T-cells was analyzed by flow cytometry. Disease activity was assessed by SLE Disease Activity Index. RESULTS: Peripheral unstimulated CD134(+) and PD-1(+) CD4(+) T-cells were significantly increased in patients with lupus nephritis. Upon stimulation both, CD134(+) and PD-1(+) CD4(+) T-cells, produced significantly less IFN-γ in SLE patients as compared to HC. The percentages of IL-22 within the CD134(+)CD4(+) T-cells were also significantly decreased in SLE as compared to HC. CONCLUSION: CD134(+) and PD-1(+)CD4(+) T-cells have mainly a Th1 effector T-cell signature. A lower proportion produces also IL-21 and IL-22. The impaired capacity to produce IFN-γ and IL-22 in SLE patients may contribute to the pathogenesis of the disease.
format Online
Article
Text
id pubmed-6643306
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66433062019-07-29 IL-22 production of effector CD4(+) T-cells is altered in SLE patients Dolff, Sebastian Scharpenberg, Claudia Specker, Christof Kribben, Andreas Witzke, Oliver Wilde, Benjamin Eur J Med Res Research BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by T-cell-dependent B-cell activation and altered T-cell response. Co-stimulatory and co-inhibitory molecules regulate and exert T-cell differentiation, survival and cytokine production. CD134(+) and PD-1(+) T-cells in SLE patients are increased in SLE. The aim of this study was to characterize CD134(+) and PD-1(+)CD4(+) T-cells according to their ability to produce IFN-γ, IL-21 and IL-22 in SLE patients. METHODS: Peripheral blood of 39 SLE patients and 19 healthy controls (HC) was stimulated with phorbol myristate acetate (PMA) calcium ionophore (Ca-Io). The expression of IFN-γ, IL-21 and IL-22 T-cells within the CD134(+) and PD-1(+) T-cells was analyzed by flow cytometry. Disease activity was assessed by SLE Disease Activity Index. RESULTS: Peripheral unstimulated CD134(+) and PD-1(+) CD4(+) T-cells were significantly increased in patients with lupus nephritis. Upon stimulation both, CD134(+) and PD-1(+) CD4(+) T-cells, produced significantly less IFN-γ in SLE patients as compared to HC. The percentages of IL-22 within the CD134(+)CD4(+) T-cells were also significantly decreased in SLE as compared to HC. CONCLUSION: CD134(+) and PD-1(+)CD4(+) T-cells have mainly a Th1 effector T-cell signature. A lower proportion produces also IL-21 and IL-22. The impaired capacity to produce IFN-γ and IL-22 in SLE patients may contribute to the pathogenesis of the disease. BioMed Central 2019-07-22 /pmc/articles/PMC6643306/ /pubmed/31331400 http://dx.doi.org/10.1186/s40001-019-0385-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dolff, Sebastian
Scharpenberg, Claudia
Specker, Christof
Kribben, Andreas
Witzke, Oliver
Wilde, Benjamin
IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title_full IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title_fullStr IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title_full_unstemmed IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title_short IL-22 production of effector CD4(+) T-cells is altered in SLE patients
title_sort il-22 production of effector cd4(+) t-cells is altered in sle patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643306/
https://www.ncbi.nlm.nih.gov/pubmed/31331400
http://dx.doi.org/10.1186/s40001-019-0385-6
work_keys_str_mv AT dolffsebastian il22productionofeffectorcd4tcellsisalteredinslepatients
AT scharpenbergclaudia il22productionofeffectorcd4tcellsisalteredinslepatients
AT speckerchristof il22productionofeffectorcd4tcellsisalteredinslepatients
AT kribbenandreas il22productionofeffectorcd4tcellsisalteredinslepatients
AT witzkeoliver il22productionofeffectorcd4tcellsisalteredinslepatients
AT wildebenjamin il22productionofeffectorcd4tcellsisalteredinslepatients